Epstein-Barr virus and carcinogenesis: Beyond Burkitt's lymphoma

Clinical Microbiology and Infection

Volumn 15, Issue 11, 2009, Pages 982-988

  Shah, K M ^a   Young, L S ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Carcinogenesis; EBV; EBV GC; Epithelial; Gastric; NPC; Review

Indexed keywords

BREAST CANCER; BURKITT LYMPHOMA; CARCINOGENESIS; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; EPITHELIUM TUMOR; EPSTEIN BARR VIRUS; GEOGRAPHIC DISTRIBUTION; HELICOBACTER PYLORI; HEREDITY; HUMAN; LIVER CANCER; MEMORY CELL; NASOPHARYNX CARCINOMA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STOMACH CARCINOMA; VIRUS LATENCY;

HUMAN HERPESVIRUS 4;

EID: 70449090036     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/j.1469-0691.2009.03033.x     Document Type: Review

References (57)

1. Burkitt D. A sarcoma involving the jaws in African children. Br J Surg 1958, 46:218-223.
2. Burkitt D. A children's cancer dependent on climatic factors. Nature 1962, 194:232-234.
3. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964, 15:702-703.
4. Henle G, Henle W. Immunofluorescence in cells derived from Burkitt's lymphoma. J Bacteriol 1966, 91:1248-1256.
5. Henle G, Henle A, Diehl V. Relation of Burkitt's tumour-associated herpestype virus to infectious mononucleosis. Proc Natl Acad Sci USA 1968, 59:94-101.
6. Henle W, Henle G, Ho HC, Burtin P, Cachin Y, Clifford P. Antibodies to Epstein-Barr virus in nasopharyngeal carcinoma, other head and neck neoplasms, and control groups. J Natl Cancer Inst 1970, 44:225-231.
7. zur Hausen H, Schulte-Holthausen H, Klein G, Henle W, Henle G, Clifford P. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 1970, 228:1056-1058.
8. Kieff E, Rickinson A, Knipe DM, Howley PM. Epstein-Barr virus and its replication. Virology 2001, 2511-2574. In, eds, Philadelphia, PA, Lipincott Williams and Wilkins Ltd
9. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004, 4:757-768.
10. Kelly G, Bell A, Rickinson A. Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat Med 2002, 8:1098-1104.
11. Cai X, Schafer A, Lu S, Bilello JP, Desrosiers RC, Edwards R. Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS Pathog 2006, 2:e23.
12. Murray PG, Young LS. Epstein-Barr virus infection: basis of malignancy and potential for therapy. Expert Rev Mol Med 2001, 15:1-20.
13. Shanmugaratnam K. Histological typing of nasopharyngeal carcinoma. IARC Sci Publ 1978, 20:3-12.
14. Chan AS, To KF, Lo KW, Ding M, Li X, Johnson P. Frequent chromosome 9p losses in histologically normal nasopharyngeal epithelia from southern Chinese. Int J Cancer 2002, 102:300-303.
15. Chan AS, To KF, Lo KW, Mak KF, Pak W, Chiu B. High frequency of chromosome 3p deletion in histologically normal nasopharyngeal epithelia from southern Chinese. Cancer Res 2000, 60:5365-5370.
16. Chan AT, Teo PM, Huang DP. Pathogenesis and treatment of nasopharyngeal carcinoma. Semin Oncol 2004, 31:794-801.
17. Lo KW, To KF, Huang DP. Focus on nasopharyngeal carcinoma. Cell 2004, 5:423-428.
18. Yu MC, Yuan JM. Epidemiology of nasopharyngeal carcinoma. Semin Cancer Biol 2002, 12:421-429.
19. Henle G, Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 1976, 17:1-7.
20. Old LJ, Boyse EA, Oettgen HF, Harven ED, Geering G, Williamson B. Precipitating antibody in human serum to an antigen present in cultured Burkitt's lymphoma Cells. Proc Natl Acad Sci USA 1966, 56:1699-1704.
21. Desgranges C, Wolf H, De-The G, Shanmugaratnam K, Cammoun N, Ellouz R. Nasopharyngeal carcinoma X. Presence of Epstein-Barr genomes in separated epithelial cells of tumours in patients from Singapore, Tunisia and Kenya. Int J Cancer 1975, 16:7-15.
22. Busson P, Keryer C, Ooka T, Corbex M. EBV-associated nasopharyngeal carcinomas: from epidemiology to virus-targeting strategies. Trends Microbiol 2004, 12:356-360.
23. Chan AT, Teo PM, Johnson PJ. Nasopharyngeal carcinoma. Ann Oncol 2002, 13:1007-1015.
24. Raab-Traub N, Flynn K. The structure of the termini of the Epstein-Barr virus as a marker of clonal cellular proliferation. Cell 1986, 47:883-889.
25. Lo KW, Huang DP. Genetic and epigenetic changes in nasopharyngeal carcinoma. Semin Cancer Biol 2002, 12:451-462.
26. Brooks L, Yao QY, Rickinson AB, Young LS. Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. J Virol 1992, 66:2689-2697.
27. Chen F, Hu LF, Ernberg I, Klein G, Winberg G. Coupled transcription of Epstein-Barr virus latent membrane protein (LMP)-1 and LMP-2B genes in nasopharyngeal carcinomas. J Gen Virol 1995, 76:131-138.
28. Heussinger N, Buttner M, Ott G, Brachtel E, Pilch BZ, Kremmer E. Expression of the Epstein-Barr virus (EBV)-encoded latent membrane protein 2A (LMP2A) in EBV-associated nasopharyngeal carcinoma. J Pathol 2004, 203:696-699.
29. Fahraeus R, Fu HL, Ernberg I, Finke J, Rowe M, Klein G. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 1988, 42:329-338.
30. Young LS, Dawson CW, Clark D, Rupani H, Busson P, Tursz T. Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol 1988, 69:1051-1065.
31. Cochet C, Martel-Renoir D, Grunewald V, Bosq J, Cochet G, Schwaab G. Expression of the Epstein-Barr virus immediate early gene, BZLF1, in nasopharyngeal carcinoma tumor cells. Virology 1993, 197:358-365.
32. Chan AT, Lo YM, Zee B, Chan LY, Ma BB, Leung SF. Plasma Epstein-Barr virus DNA and residual disease after radiotherapy for undifferentiated nasopharyngeal carcinoma. J Natl Cancer Inst 2002, 94:1614-1619.
33. Hui AB, Lo KW, Teo PM, To KF, Huang DP. Genome wide detection of oncogene amplifications in nasopharyngeal carcinoma by array based comparative genomic hybridization. Int J Oncol 2002, 20:467-473.
34. Wong N, Hui AB, Fan B, Lo KW, Pang E, Leung SF. Molecular cytogenetic characterization of nasopharyngeal carcinoma cell lines and xenografts by comparative genomic hybridization and spectral karyotyping. Cancer Genet Cytogenet 2003, 140:124-132.
35. Wang GL, Lo KW, Tsang KS, Chung NY, Tsang YS, Cheung ST. Inhibiting tumorigenic potential by restoration of p16 in nasopharyngeal carcinoma. Br J Cancer 1999, 81:1122-1126.
36. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric adenocarcinoma: review and considerations for future directions. Ann Surg 2005, 241:27-39.
37. Takada K. Epstein-Barr virus and gastric carcinoma. Mol Pathol 2000, 53:255-261.
38. Osato T, Imai S. Epstein-Barr virus and gastric carcinoma. Semin Cancer Biol 1996, 7:175-182.
39. Niedobitek G, Herbst H, Young LS, Rowe M, Dienemann D, Germer C. Epstein-Barr virus and carcinomas. Expression of the viral genome in an undifferentiated gastric carcinoma. Diagn Mol Pathol 1992, 1:103-108.
40. Shibata D, Weiss LM. Epstein-Barr virus-associated gastric adenocarcinoma. Am J Pathol 1992, 140:769-774.
41. Campos F, Carrasquilla G, Koriyama C, Serra M, Carrascal E, Itoh T. Risk factors of gastric cancer specific for tumor location and histology in Cali, Colombia. World J Gastroenterol 2006, 12:5772-5779.
42. Imai S, Koizumi S, Sugiura M, Tokunaga M, Uemura Y, Yamamoto N. Gastric carcinoma: monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci USA 1994, 91:9131-9135.
43. Chang MS, Uozaki H, Chong JM, Ushiku T, Sakuma K, Ishikawa S. CpG island methylation status in gastric carcinoma with and without infection of Epstein-Barr virus. Clin Cancer Res 2006, 12:2995-3002.
44. Lee HS, Chang MS, Yang HK, Lee BL, Kim WH. Epstein-barr virus-positive gastric carcinoma has a distinct protein expression profile in comparison with Epstein-Barr virus-negative carcinoma. Clin Cancer Res 2004, 10:1698-1705.
45. Schneider BG, Gulley ML, Eagan P, Bravo JC, Mera R, Geradts J. Loss of p16/CDKN2A tumor suppressor protein in gastric adenocarcinoma is associated with Epstein-Barr virus and anatomic location in the body of the stomach. Human Pathol 2000, 31:45-50.
46. van Rees BP, Caspers E, zur Hausen A, van den Brule A, Drillenburg P, Weterman MA. Different pattern of allelic loss in Epstein-Barr virus-positive gastric cancer with emphasis on the p53 tumor suppressor pathway. Am J Pathol 2002, 161:1207-1213.
47. Zur Hausen A, van Rees BP, van Beek J, Craanen ME, Bloemena E, Offerhaus GJ. Epstein-Barr virus in gastric carcinomas and gastric stump carcinomas: a late event in gastric carcinogenesis. J Clin Pathol 2004, 57:487-491.
48. Bonnet M, Guinebretiere JM, Kremmer E, Grunewald V, Benhamou E, Contesso G. Detection of Epstein-Barr virus in invasive breast cancers. J Natl Cancer Inst 1999, 91:1376-1381.
49. Sugawara Y, Mizugaki Y, Uchida T, Torii T, Imai S, Makuuchi M. Detection of Epstein-Barr virus (EBV) in hepatocellular carcinoma tissue: a novel EBV latency characterized by the absence of EBV-encoded small RNA expression. Virology 1999, 256:196-202.
50. Huang J, Chen H, Hutt-Fletcher L, Ambinder RF, Hayward SD. Lytic viral replication as a contributor to the detection of Epstein-Barr virus in breast cancer. J Virol 2003, 77:13267-13274.
51. Junying J, Herrmann K, Davies G, Lissauer D, Bell A, Timms J. Absence of Epstein-Barr virus DNA in the tumor cells of European hepatocellular carcinoma. Virology 2003, 306:236-243.
52. Shimizu N, Yoshiyama H, Takada K. Clonal propagation of Epstein-Barr virus (EBV) recombinants in EBV-negative Akata cells. J Virol 1996, 70:7260-7263.
53. Chan KC, Lo YM. Clinical applications of plasma Epstein-Barr virus DNA analysis and `protocols for the quantitative analysis of the size of circulating Epstein-Barr virus DNA. Methods Mol Biol (Clifton NJ) 2006, 336:111-121.
54. Straathof KC, Bollard CM, Popat U, Huls MH, Lopez T, Morriss MC. Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood 2005, 105:1898-1904.
55. Li JH, Shi W, Chia M, Sanchez-Sweatman O, Siatskas C, Huang D. Efficacy of targeted FasL in nasopharyngeal carcinoma. Mol Ther 2003, 8:964-973.
56. Duraiswamy J, Sherritt M, Thomson S, Tellam J, Cooper L, Connolly G. Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma. Blood 2003, 101:3150-3156.
57. Xu JJ, Yao K, Yu CJ, Chen X, Lu MP, Sun H. Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells. Auris Nasus Larynx 2006, 33:441-446.